Rapport Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-111.5M | $-78.3M | $-34.8M |
| Depreciation & Amortization | $1.0M | $839.0K | $112.0K |
| Depreciation | $1.0M | $800.0K | $100.0K |
| Amortization | — | — | — |
| Stock-Based Compensation | $18.9M | $10.2M | $3.5M |
| Net Cash from Operating Activities | $-87.5M | $-64.8M | $-27.2M |
| Investing Activities | |||
| Capital Expenditures | $616.0K | $2.4M | $1.6M |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-187.5M | $-170.1M | $-78.9M |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $270.8M | $221.6M | $145.1M |
| Net Change in Cash | $-4.2M | $-13.3M | $39.1M |
| Free Cash Flow | $-88.1M | $-67.2M | $-28.8M |